MLI Stock Chart & Stats
€83.00
-€4.00(-2.92%)
At close: 4:00 PM EST
€83.00
-€4.00(-2.92%)
Day’s Range― - ―
52-Week Range€48.80 - €93.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€478.32M
Enterprise Value€632.10
Total Cash (Recent Filing)€26.93M
Total Debt (Recent Filing)€155.17M
Price to Earnings (P/E)82.1
Beta0.82
Next Earnings
Jul 30, 2026EPS Estimate
2.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.23
Shares Outstanding5,595,869
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.62
Price to Sales (P/S)1.96
P/FCF Ratio12.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€82.15Price Target Upside-1.02% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)7.43
Revenue Forecast (FY)€223.38M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueMesa’s core sterilization and clinical genomics products are consumable, driving repeat purchases from regulated hospitals and labs. This creates predictable, recurring revenue streams tied to compliance needs, supporting volume stability and long-term cash visibility across inspection and accreditation cycles.
Consistent Free Cash Flow GenerationReliable positive operating and free cash flows—even through the 2024 earnings downturn—provide durable financial flexibility. Strong FCF supports reinvestment, working capital, and deleveraging, reducing reliance on external financing and enabling steady funding of R&D and service capabilities.
Healthy Gross Margins & Recent Revenue Step-upSustained high gross margins reflect structural pricing power and product mix advantage in specialized QA instruments and consumables. Combined with the 2026 revenue step-up, this supports scalable operating leverage and the potential to convert higher top-line into durable improvement in operating performance.
Bears Say
Earnings VolatilityLarge swings in profitability reduce predictability for cash flow and returns. Intermittent heavy losses can interrupt investment plans, strain stakeholder confidence, and complicate long-range forecasting, implying higher operational and execution risk relative to more stable peers.
Balance-sheet Swings And Past LeverageHistorical leverage volatility indicates the company’s capital structure can deteriorate in stress periods, constraining flexibility. Periodic heavy leverage raises refinancing and interest-rate risks, potentially limiting M&A or investment capacity during downcycles and increasing vulnerability to margin shocks.
CEO Departure / Leadership TransitionA CEO exit is a structural leadership change that can disrupt strategic execution, customer and employee relationships, and near-term planning. Even with a transition agreement, succession risk can slow decision-making and create uncertainty around long-term strategy and culture during the handover period.
Mesa Laboratories News
MLI FAQ
What was Mesa Laboratories’s price range in the past 12 months?
Mesa Laboratories lowest stock price was €48.80 and its highest was €93.00 in the past 12 months.
What is Mesa Laboratories’s market cap?
Mesa Laboratories’s market cap is €478.32M.
When is Mesa Laboratories’s upcoming earnings report date?
Mesa Laboratories’s upcoming earnings report date is Jul 30, 2026 which is in 6 days.
How were Mesa Laboratories’s earnings last quarter?
Mesa Laboratories released its earnings results on May 27, 2026. The company reported €2.898 earnings per share for the quarter, beating the consensus estimate of €1.831 by €1.067.
Is Mesa Laboratories overvalued?
According to Wall Street analysts Mesa Laboratories’s price is currently Overvalued.
Does Mesa Laboratories pay dividends?
Mesa Laboratories does not currently pay dividends.
What is Mesa Laboratories’s EPS estimate?
Mesa Laboratories’s EPS estimate is 2.31.
How many shares outstanding does Mesa Laboratories have?
Mesa Laboratories has 5,595,869 shares outstanding.
What happened to Mesa Laboratories’s price movement after its last earnings report?
Mesa Laboratories reported an EPS of €2.898 in its last earnings report, beating expectations of €1.831. Following the earnings report the stock price went down -2.703%.
Which hedge fund is a major shareholder of Mesa Laboratories?
Currently, no hedge funds are holding shares in DE:MLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesa Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€82.15 (-1.02% Downside)
€82.15 (-1.02% Downside)
Blogger Sentiment
Bullish
DE:MLI Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth €417.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.88%
12-Months-Change
Fundamentals
Return on Equity
0.65%
Trailing 12-Months
Asset Growth
-1.29%
Trailing 12-Months
Company Description
Mesa Laboratories
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
MLI Stock 12 Month Forecast
Average Price Target
€82.15
▼(-1.02% Downside)
Technical Analysis
Daktronics
―
Lightpath Technologies
―
Lsi Industries
―
Richardson Electronics
―
Vishay Precision Group
―